Monitoring bortezomib therapy in multiple myeloma: Screening of cyclin D1, D2, and D3 via reliable real-time polymerase chain reaction and association with clinico-pathological features and outcome

Leukemia and Lymphoma

Volumn 51, Issue 9, 2010, Pages 1632-1642

  Thanh Truc Ngo, Ba ^a   Felthaus, Julia ^a   Hein, Manuel ^a   Follo, Marie ^a   Wider, Dagmar ^a   Ihorst, Gabriele ^a   Engelhardt, Monika ^a   Wäsch, Ralph ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Bortezomib; cell cycle; cyclin D1; multiple myeloma; proteasome; ubiquitin

Indexed keywords

BORTEZOMIB; CYCLIN D1; CYCLIN D2; CYCLIN D3;

ADULT; AGED; ARTICLE; BONE MARROW; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; MALE; MULTIPLE MYELOMA; PILOT STUDY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT RESPONSE; TUMOR GROWTH;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BONE MARROW; BORONIC ACIDS; CYCLIN D1; CYCLIN D2; CYCLIN D3; DNA; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM RECURRENCE, LOCAL; PILOT PROJECTS; POLYMERASE CHAIN REACTION; PYRAZINES; SALVAGE THERAPY; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 77956301225     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2010.496014     Document Type: Article

References (33)

1. Malumbres M, Barbacid M. To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer 2001;1:222-231.
2. Ishii Y, Pirkmaier A, Alvarez JV, et al. Cyclin D1 overexpression and response to bortezomib treatment in a breast cancer model. J Natl Cancer Inst 2006;98:1238-1247.
3. Soverini S, Cavo M, Cellini C, et al. Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation. Blood 2003;102:1588-1594.
4. Kuehl WM, Bergsagel PL. Early genetic events provide the basis for a clinical classification of multiple myeloma. Hematology Am Soc Hematol Educ Program 2005;346-352.
5. Agnelli L, Bicciato S, Mattioli M, et al. Molecular classification of multiple myeloma: a distinct transcriptional profile characterizes patients expressing CCND1 and negative for 14q32 translocations. J Clin Oncol 2005;23:7296-7306.
6. Hanamura I, Huang Y, Zhan F, Barlogie B, Shaughnessy J. Prognostic value of cyclin D2 mRNA expression in newly diagnosed multiple myeloma treated with high-dose chemotherapy and tandem autologous stem cell transplantations. Leukemia 2006;20:1288-1290.
7. Ely S, Di Liberto M, Niesvizky R, et al. Mutually exclusive cyclin-dependent kinase 4/cyclin D1 and cyclin-dependent kinase 6/cyclin D2 pairing inactivates retinoblastoma protein and promotes cell cycle dysregulation in multiple myeloma. Cancer Res 2005;65:11345-11353.
8. Zlei M, Egert S, Wider D, Ihorst G, Wäsch R, Engelhardt M. Characterization of in vitro growth of multiple myeloma cells. Exp Hematol 2007;35:1550-1561.
9. Wäsch R, Engelbert D. Anaphase-promoting complex-dependent proteolysis of cell cycle regulators and genomic instability of cancer cells. Oncogene 2005;24:1-10.
10. Quintanilla-Martinez L, Kremer M, Specht K, et al. Analysis of signal transducer and activator of transcription 3 (Stat 3) pathway in multiple myeloma: Stat 3 activation and cyclin D1 dysregulation are mutually exclusive events. Am J Pathol 2003;162:1449-1461.
11. Bartkova J, Lukas J, Strauss M, Bartek J. Cell cycle-related variation and tissue-restricted expression of human cyclin D1 protein. J Pathol 1994;172:237-245.
12. Rasmussen T, Knudsen LM, Johnsen HE. Frequency and prognostic relevance of cyclin D1 dysregulation in multiple myeloma. Eur J Haematol 2001;67:296-301.
13. Denz U, Haas PS, Wäsch R, Einsele H, Engelhardt M. State of the art therapy in multiple myeloma and future perspectives. Eur J Cancer 2006;42:1591-1600.
14. Katzel JA, Hari P, Vesole DH. Multiple myeloma: charging toward a bright future. CA Cancer J Clin 2007;57:301-318.
15. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487-2498.
16. Richardson P, Mitsiades C, Schlossman R, et al. The treatment of relapsed and refractory multiple myeloma. Hematology Am Soc Hematol Educ Program 2007;317-323.
17. Mateos MV, Hernandez JM, Hernandez MT, et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood 2006;108:2165-2172.
18. Specht K, Kremer M, Muller U, et al. Identification of cyclin D1 mRNA overexpression in B-cell neoplasias by real-time reverse transcription-PCR of microdissected paraffin sections. Clin Cancer Res 2002;8:2902-2911.
19. Medeiros LJ, Hai S, Thomazy VA, Estalilla OC, Romaguera J, Luthra R. Real-time RT-PCR assay for quantifying cyclin D1 mRNA in B-cell non-Hodgkin's lymphomas. Mod Pathol 2002;15:556-564.
20. Specht K, Haralambieva E, Bink K, et al. Different mechanisms of cyclin D1 overexpression in multiple myeloma revealed by fluorescence in situ hybridization and quantitative analysis of mRNA levels. Blood 2004;104:1120-1126.
21. Jagannath S, Richardson PG, Sonneveld P, et al. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia 2007;21:151-157.
22. Engelhardt M, Mertelsmann R. 160 years of multiple myeloma: progress and challenges. Eur J Cancer 2006;42: 1507-1509.
23. Zhan F, Hardin J, Kordsmeier B, et al. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood 2002;99:1745-1757.
24. Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 2007;7:585-598.
25. Anderson KC, Shaughnessy JD Jr, Barlogie B, Harousseau JL, Roodman GD. Multiple myeloma. Hematology Am Soc Hematol Educ Program 2002;214-240.
26. Shaughnessy J, Jacobson J, Sawyer J, et al. Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expression. Blood 2003;101:3849-3856.
27. Smadja NV, Bastard C, Brigaudeau C, Leroux D, Fruchart C. Hypodiploidy is a major prognostic factor in multiple myeloma. Blood 2001;98:2229-2238.
28. Bezieau S, Devilder MC, Avet-Loiseau H, et al. High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis. Hum Mutat 2001;18:212-224.
29. Bergsagel PL, Chesi M, Nardini E, Brents LA, Kirby SL, Kuehl WM. Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma. Proc Natl Acad Sci USA 1996;93:13931-13936.
30. Engelhardt M, Muller AM, Maier W, Wäsch R. Severe irreversible bilateral hearing loss after bortezomib (VELCADE) therapy in a multiple myeloma (MM) patient. Leukemia 2005;19:869-70.
31. Terpos E, Katodritou E, Tsiftsakis E, et al. Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration. Haematologica 2009;94:372-379.
32. Kleber M, Ihorst G, Deschler B, et al. Detection of renal impairment as one specific comorbidity factor in multiple myeloma: multicenter study in 198 consecutive patients. Eur J Haematol 2009;83:519-527.
33. Dawson MA, Opat SS, Taouk Y, et al. Clinical and immunohistochemical features associated with a response to bortezomib in patients with multiple myeloma. Clin Cancer Res 2009;15:714-722.